1,163 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B Downtrend
Article Searches
Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC http://www.zacks.com/stock/news/338106/bristol-myers-opdivo-receives-positive-chmp-opinion-for-rcc?cid=CS-ZC-FT-338106 Nov 16, 2018 - Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with low-dose Yervoy gets positive opinion from CHMP for the treatment of intermediate- and poor-risk advanced RCC.
uniQure Up on Positive Data From Mid-Stage Hemophilia Study http://www.zacks.com/stock/news/337966/uniqure-up-on-positive-data-from-mid-stage-hemophilia-study?cid=CS-ZC-FT-337966 Nov 16, 2018 - uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.
CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX-2009 https://seekingalpha.com/article/4222467-cytomx-translational-data-cxminus-072-point-towards-positive-readout-cxminus-2009?source=feed_tag_editors_picks Nov 15, 2018 -
Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug http://www.zacks.com/stock/news/337863/mallinckrodt-gets-fda-committee-vote-for-abuse-deterrent-drug?cid=CS-ZC-FT-337863 Nov 15, 2018 - The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx http://www.zacks.com/stock/news/337748/exelixis-ipsen-get-eu-nod-for-label-expansion-of-cabometyx?cid=CS-ZC-FT-337748 Nov 15, 2018 - Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.
Ziopharm: Elucidating The Regeneron Partnership For Glioblastoma https://seekingalpha.com/article/4222105-ziopharm-elucidating-regeneron-partnership-glioblastoma?source=feed_sector_healthcare Nov 14, 2018 -
Merck Starts Rolling BLA Submission for Ebola Vaccine V920 http://www.zacks.com/stock/news/337545/merck-starts-rolling-bla-submission-for-ebola-vaccine-v920?cid=CS-ZC-FT-337545 Nov 14, 2018 - Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.
Shire's Filing Accepted by FDA for Gattex's Label Expansion http://www.zacks.com/stock/news/337411/shires-filing-accepted-by-fda-for-gattexs-label-expansion?cid=CS-ZC-FT-337411 Nov 14, 2018 - The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark http://www.zacks.com/stock/news/337032/aveo-pharmaceuticals-aveo-q3-earnings-revenues-top-mark?cid=CS-ZC-FT-337032 Nov 12, 2018 - AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.
Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat http://www.zacks.com/stock/news/336822/endo-endp-stock-declines-despite-q3-earnings-revenue-beat?cid=CS-ZC-FT-336822 Nov 09, 2018 - Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.

Pages: 123456...117

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
AZN Astrazeneca PLC NYSE $37.56 $95.16B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Bristol-Myers Squibb Company